**Update: The US FDA Antimicrobial Drug Advisory Committee voted in favor of the NDA 14 to 4 on June 6th, 2019**
The United States Food & Drug Administration (FDA) will host the Antimicrobial Drug Advisory Committee on Thursday, June 6th to discuss the new drug application (NDA) involving new chemical entity, pretomanid, in combination with bedaquiline and linezolid in an all-oral 6-month defined regimen for adults with extensively drug resistant (XDR) tuberculosis or treatment-intolerant or non-responsive multidrug resistant (MDR) tuberculosis submitted by TB Alliance.
The FDA will provide a live web broadcast of the meeting which will take place from 8AM to 4PM. A link to the broadcast can be found here: webcast.
A link to the agenda of the meeting can be found here: June 6th, 2019 Antimicrobial Drug Advisory Committee Meeting Agenda.
Further materials relating to the NDA and meeting can be found here: meeting materials.
For more information about Pretomanid, please visit the WGND compound page on Pretomanid where you can view links to clinical trials and regimens involving Pretomanid.